维昇药业-B

开始申购 2025-03-13

未上市

社区社区
资讯资讯
资料资料
公告公告

- 最新
- 推荐
公司概况
公司名称
维昇药业－Ｂ
所属市场
SEHK
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
- -
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
维昇药业成立于2018年11月，是一家处于研发后期、产品接近商业化的生物制药公司，专注于在中国（包括香港、澳门及台湾）提供特定内分泌疾病的治疗方案。核心产品为隆培促生长素(lonapegsomatropin)，每周一次的长效生长激素替代疗法，用于治疗儿童生长激素缺乏症（PGHD）。另有两款关键候选药物：那韦培肽(navepegritide)，C型利钠肽的长效前药，用于治疗软骨发育不全；以及帕罗培特立帕肽(palopegteriparatide)，每日一次的甲状旁腺激素替代疗法，用于治疗慢性甲状旁腺功能减退症
- 03-13 06:14
  股份发售
  全球发售
  全球发售

2025-03-13

招股说明书查看招股说明书

2025-03-13

发行信息

价格范围
68.440 - 75.280HKD
发售规模
1.12亿
市值
76.96亿-84.65亿
最小购买量
100
杠杆率
待定

2025-03-18

已休市

发行价格
待定

2025-03-20

中签日

抽签率
待定

2025-03-21

上市

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

老虎社区侵权投诉指引

中国互联网举报中心·北京互联网举报中心

网络谣言曝光台·扫黄打非举报中心

网络110报警服务

© 2018-2025 老虎社区版权所有

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

qrcode

关注我们

{"pagemeta":{"title":"维昇药业-B(02561)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维昇药业-B(02561)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维昇药业-B,02561,维昇药业-B股票,维昇药业-B股票老虎,维昇药业-B股票老虎国际,维昇药业-B行情,维昇药业-B股票行情,维昇药业-B股价,维昇药业-B股市,维昇药业-B股票价格,维昇药业-B股票交易,维昇药业-B股票购买,维昇药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维昇药业-B(02561)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维昇药业-B(02561)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"fillings","symbol":"02561","data":{"stockData":{"symbol":"02561","market":"HK","secType":"STK","nameCN":"维昇药业-B","latestPrice":0,"timestamp":1741939200000,"preClose":0,"halted":7,"volume":0,"delay":0,"floatShares":112441864,"shares":112441864,"eps":0,"marketStatus":"待上市","change":0,"latestTime":"03-14 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1742520600000},"marketStatusCode":8,"adr":0,"listingDate":1742486400000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1741915800000,1741924800000],[1741928400000,1741939200000]],"volumeRatio":0,"ipoDetail":{"name":"维昇药业－Ｂ","exchange":"SEHK","listingDate":"2025-03-21","sharesOutstanding":112441864,"sharesFloat":112441864,"offerAmount":9900000,"priceRange":"68.440 - 75.280","market":"HK","openProspectusDate":"2025-03-13","openProspectusUrl":"https://staticpdf.iqdii.com/stockdata/notice/02561/2025/2025031300018_c.pdf","purchaseBeginDate":"2025-03-13","purchaseEndDate":"2025-03-18","winningDate":"2025-03-20","currency":"HKD","minPurchaseQuantity":100,"use":"1、约506.9百万港元（占84.0%）用于为正在进行的进口核心产品的BLA注册，正在进行的及计划中的本地生产核心产品的研发及BLA注册，计划中的新适应症扩展临床试验，以及核心产品隆培促生长素 (lonapegsomatropin)的计划商业化上市提供资金；\n2、约45.7百万港元（占7.6%）用于为正在进行的帕罗培特立帕肽(palopegteriparatide)的中国3期关键性试验的开放标签扩展研究部分及商业化上市的筹备工作提供资金；\n3、约10.7百万港元（占1.8%）用于为正在进行的那韦培肽 (navepegritide)用于治疗软骨发育不全的中国2期试验的开放标签扩展研究部分及相关分析提供资金；\n4、约40.0百万港元（占6.6%）用于拨付营运资金及作其他一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司是一家处于研发后期、产品接近商业化的生物制药公司，专注于在中国（包括香港、澳门及台湾）提供特定内分泌疾病的治疗方案。","subscribed":17.85,"marketCap":7695999999.999999,"minimumCapital":7603.92,"overAllotment":true,"lotSize":100,"issueOpenRate":0.1,"subscribeGear":"100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,20000,30000,40000,50000,60000,70000,80000,90000,100000,150000,200000,250000,300000,350000,400000,450000,495000"},"greyMarketDetail":{"greyDate":"2025-03-20","greyDateTimestamp":1742400000000,"greyOpeningTime":1742458500000,"greyClosingTime":1742466600000,"showGreyQuote":false,"openProspectusDate":"2025-03-13","listingDate":"2025-03-21"},"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"tweetData":null,"newsData":null,"noticeData":{"listData":[{"cdn_pdf":true,"hasAttachments":false,"id":"19232777","market":"hk","labels":[],"media":"港交所","original_id":"N.HK4bwi4bC9ha","pdf_url":"https://static.tigerbbs.com/061a491568ea4cb3bc3199701afb1b9c","pub_time":1741817640000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"全球发售","symbol":"02561","title":"全球发售","titleType":"股份发售","type":"hkIPO","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0313/2025031300018_c.pdf","us_notice_code":"上市文件 - [发售以供认购]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"上市文件","type_name_en":"Listing Document","titleTypeEn":"Shares Subscription","event_type":"important_notice","event_name":"股份发售","pubTime":"2025-03-13 06:14","pubTimestamp":1741817640,"notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":true},"companyData":{"profile":{"compareEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":0.0962},{"period":"3month","weight":0.1997},{"period":"6month","weight":0.3795},{"period":"1year","weight":0.4126},{"period":"ytd","weight":0.1944}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"维昇药业成立于2018年11月，是一家处于研发后期、产品接近商业化的生物制药公司，专注于在中国（包括香港、澳门及台湾）提供特定内分泌疾病的治疗方案。核心产品为隆培促生长素(lonapegsomatropin)，每周一次的长效生长激素替代疗法，用于治疗儿童生长激素缺乏症（PGHD）。另有两款关键候选药物：那韦培肽(navepegritide)，C型利钠肽的长效前药，用于治疗软骨发育不全；以及帕罗培特立帕肽(palopegteriparatide)，每日一次的甲状旁腺激素替代疗法，用于治疗慢性甲状旁腺功能减退症","exchange":"SEHK","name":"维昇药业-B","nameEN":"VISEN PHARMA-B"},"aProfile":null}}}